<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We evaluated the effects of <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> (4 mg b.i.d.) and <z:chebi fb="0" ids="6801">metformin</z:chebi> (1 g b.i.d.) monotherapy for 26 weeks on adipose tissue insulin-stimulated <z:chebi fb="105" ids="17234">glucose</z:chebi> uptake in patients (n = 41) with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>Before and after the treatment, <z:chebi fb="105" ids="17234">glucose</z:chebi> uptake was measured using 2-[(18)F]fluoro-2-<z:chebi fb="0" ids="15866">deoxyglucose</z:chebi> and <z:chebi fb="4" ids="30225">positron</z:chebi> emission tomography and adipose tissue masses were quantified using magnetic resonance imaging </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="0" ids="50122">Rosiglitazone</z:chebi> improved insulin-stimulated whole-body <z:chebi fb="105" ids="17234">glucose</z:chebi> uptake by 44% (P &lt; 0.01 vs. placebo) </plain></SENT>
<SENT sid="3" pm="."><plain>Mean body weight was unchanged in the <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> group, while it decreased by 2.0 kg in the <z:chebi fb="0" ids="6801">metformin</z:chebi> group (P &lt; 0.05 vs. placebo) </plain></SENT>
<SENT sid="4" pm="."><plain>In visceral adipose tissue, <z:chebi fb="105" ids="17234">glucose</z:chebi> uptake increased by 29% (from 17.8 +/- 2.0 to 23.0 +/- 2.6 micro mol x kg(-1) x min(-1), P &lt; 0.05 vs. placebo) in the <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> group but to a lesser extent (17%) in the <z:chebi fb="0" ids="6801">metformin</z:chebi> group (from 16.2 +/- 1.5 to 18.9 +/- 1.7 micro mol x kg(-1) x min(-1), P &lt; 0.05 vs. baseline) </plain></SENT>
<SENT sid="5" pm="."><plain>Because the visceral adipose tissue mass simultaneously decreased with both treatments (P &lt; 0.05), no change was observed in total visceral <z:chebi fb="105" ids="17234">glucose</z:chebi> uptake per depot </plain></SENT>
<SENT sid="6" pm="."><plain><z:chebi fb="0" ids="50122">Rosiglitazone</z:chebi> significantly enhanced <z:chebi fb="105" ids="17234">glucose</z:chebi> uptake in the femoral subcutaneous area, either when expressed per tissue mass (from 10.8 +/- 1.2 to 17.1 +/- 1.7 micro mol x kg(-1) x min(-1), P &lt; 0.01 vs. placebo) or per whole-fat depot (P &lt; 0.05 vs. placebo) </plain></SENT>
<SENT sid="7" pm="."><plain>In conclusion, <z:chebi fb="0" ids="6801">metformin</z:chebi> treatment resulted in improvement of glycemic control without enhancement of peripheral insulin sensitivity </plain></SENT>
<SENT sid="8" pm="."><plain>The improved insulin sensitivity of the nonabdominal subcutaneous adipose tissue during treatment with <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> partly explains the enhanced whole-body insulin sensitivity and underlies the central role of adipose tissue for action of peroxisome proliferator-activated receptor gamma <z:chebi fb="4" ids="48705">agonist</z:chebi> in vivo </plain></SENT>
</text></document>